ALCOHOLIC CARDIOMYOPATHY: BASIC ASPECTS OF EPIDEMIOLOGY, PATHOGENESIS AND PHARMACOTHERAPY
https://doi.org/10.20996/1819-6446-2014-10-6-651-658
Abstract
Data on the epidemiology and pathogenesis of alcoholic cardiomyopathy (ACMP) are presented. Special aspects of clinical manifestations as well as management of these patients are considered. Psychotropic therapy aimed at reduction in motivation to alcohol consumption in patients with ACMP is discussed separately.
About the Author
A. O. Yusupova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
References
1. WHO to meet beverage company representatives to discuss health-related alcohol issues. Available at: http://www.who.int/mediacentre/news/releases/2003/pr6/en/. Accessed by 10.12.2014.
2. The physician’s guide to helping patients with alcohol problems. National Institutes of Health publication no. 95-3769. Washington DC: U.S. Department of Health and Human Services; 1995.
3. Nutrition and your health: dietary guidelines for Americans. 4th ed. Home and Garden Bulletin. Washington DC: U.S. Department of Health and Human Services, Department of Agriculture (USDA); 1995.
4. Saremi A, Arora R. The cardiovascular implications of alcohol and red wine. Am J Ther 2008; 15(3):265-77.
5. Schukit MA. ed. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. NewYork, NY: Plenum Medical Book Company; 1995.
6. Schorling JB, Buchsbaum DG. Screening for alcohol and drug abuse. Med Clin North Am 1997;81:845-65.
7. Popova S, Rehm J, Patra J. Comparing alcohol consumption in central and eastern Europe to other European countries. Alcohol and Alcoholism 2007;42 (5):465-73.
8. Anderson P, Baumberg B, eds. Alcohol in Europe: a public health persepctive. A report for the European Commission. Luxembourg: European Communities; 2006.
9. Leon DA, Chenet L, Shkolnikov VM, et al. Huge variation in Russian mortality rates 1984-94: artefact, alcohol, or what? Lancet 1997; 350(9075): 383-8.
10. Zatonski WA, Jha P. The Health Transformation in Eastern Europe After 1990: A Second Look. Warsaw: Marie Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; 2000.
11. Iluk RD, RybakovaKV, Kiselev AS et al. Epidemiology and medico-social characteristics depending on beer and spirits. Zhurnal Nevrologii i Psikhiatrii 2011; (11): 3-13. Russian (Илюк Р. Д.,Рыбакова К.В., Киселёв А. С. И др. Эпидемиология и медико-социальные особенности зависимости от пива и крепких алкогольных напитков. Журнал Неврологии и Психиатрии 2011;(11): 3-13).
12. Healthcare in Russia, in 2013. Statistical collection. Moscow: Rosstat; 2013. Russian (Здравоохранение в России, 2013. Статистический сборник. Москва: Росстат; 2013).
13. Koshkina EA, Kirzhanova VV, Guseva OI, et al. Providing drug treatment population of the Russian Federation in 2012. Voprosy Narkologii 2013; (4): 3-18. Russian (Кошкина Е.А., Киржанова В.В., Гусева О.И. и др. Оказание наркологической помощи населению российской федерации в 2012 г. Вопросы Наркологии 2013; (4): 3-18).
14. Hookana E, Junttila MJ, Puurunen VP, et al. Causes of nonischemic sudden cardiac death in the current era. Heart rhythm: the official journal of the Heart Rhythm Society 2011;8:1570-5.
15. Vital and Health Statistics, October 1995; 13 (122). Hyattsville, MD: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention; 1995.
16. Fauchier L, Babuty D, Poret P. et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000;21:306-14.
17. McKenna CJ, Codd MB, McCann HA et al. Alcohol consumption idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135: 833-7.
18. Gavazzi A, De Maria R, Parolini M et al. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol2000; 85: 1114-8.
19. Fernández-SolàJ, Estruch R, Nicolás J-M et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80: 481-5.
20. Rehm J, Sempos C, Trevisan M. Average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease–a review. Journal of Cardiovascular Risk 2003; 10: 15-20.
21. Skotzko CE, Vrinceanu A, Krueger L, et al. Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking. Heart Fail Rev 2009; 14(1): 51-5.
22. Pavlova LI. Effect of alcohol on the occurrence of coronary heart disease. Lechashchiy Vrach 1998; (5): 5-7. Russian (Павлова Л. И. Влияние алкоголя на возникновение ишемической болезни сердца. Лечащий Врач 1998;(5): 5-7).
23. Kupari M, Koskinen P, Suokas A, et al. Left ventricular filling impairment in asymptomatic chronic alcoholics. Am J Cardiol 1990; 66: 1473-7 .
24. Lazarevic AM, Nakatani S, Neskovic AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35:1599-606.
25. Askanas A, Udoshi M, Sadjadi SA. The heart in chronic alcoholism: a noninvasive study. Am Heart J 1980;99: 9-16.
26. Silberbauer K, Juhasz M, Ohrenberger G. et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in young alcoholics. Cardiology 1988; 75: 431-9.
27. Mathews EC, Gradin JM, Henry WL et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47: 570-8
28. Urbano-Márquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-15.
29. Moiseyev VS, Shelepin AA. Alcohol and heart disease: a guide. Moscow: GEOTAR Media; 2009. Russian (Моисеев В.С., Шелепин А.А. Алкоголь и болезни сердца: руководство. М.: ГЭОТАР-Медиа; 2009).
30. Meehan, J, Piano, MR, Solaro, RJ, et al.Heavy long-term ethanol consumption induces an α- to β-myosin heavy chain isoforms transition in rat. Basic Res Cardiol 1999; 94: 481-8.
31. Law BA, Carver WE. Activation of cardiac fibroblasts by ethanol is blocked by TGF-βinhibition. Alcohol Clin Exp Res 2013;37(8):1286-94.
32. Zhang RH, Gao JY, Guo HT. Inhibition of CYP2E1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction and apoptosis. Biochim BiophysActa 2013; 1832(1): 128-41.
33. Chen DB, Wang L, Wang PH. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sci 2000; 67: 1683-93.
34. Hu C, Ge F, Hyodo E. Chronic ethanol consumption increases cardiomyocyte fatty acid uptake and decreases ventricular contractile function in C57BL/6J mice. J Mol Cell Cardiol 2013; 59: 30-40.
35. Dancy M, Leech G, Bland JM et al. Preclinical left ventricular abnormalities in alcoholic are independent of nutritional status, cirrhosis and cigarette smoking. Lancet1985;1:1122-5.
36. Astashkina OG, Vlasova NV The diagnostic method of death from coronary heart disease and alcoholic cardiomyopathy: Application № 2007136747. Inventions. Utility Models: e-newsletter 2008; (2). Available at: http://www1.fips.ru/Electronic_bulletin/Inventions_and_utility_models/02_08/Index_ru.htm. Accessed by 12/10/2014. Russian (Асташкина О. Г., Власова Н. В. Способ диагностики смерти от ишемической болезни сердца и алкогольной кардиомиопатии: заявка № 2007136747. Изобретения. Полезные модели: электронный бюллетень 2008; (2). Доступно на: http://www1.fips.ru/Electronic_bulletin/Inventions_and_utility_models/02_08/Index_ru.htm. Проверено 10.12.2014)
37. Smith-Warner SA, Spiegelman D, Yaun SS et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA1998;279:535-40.
38. Kino M, Imamitchi H, Morigutchi M, et al. Cardiovascular status in asymptomatic alcoholics, with reference to the level of ethanol consumption. Br Heart J 1981; 46: 545-51.
39. Kupari M, Koskinen P, Suokas A. Left ventricular size, mass and function in relation to the duration and quantity of heavy drinking in alcoholics. Am J Cardiol 1991; 67: 274-9.
40. Prazak P, Pfisterer M, Osswald S et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic cardiomyopathy. Eur Heart J1996;17:251-7.
41. George А, Figueredo VM. Alcoholic cardiomyopathy: a review. J Card Fail 2011;17(10):844-9.
42. Montalto NJ, Bean P. Use of contemporary biomarkers in the detection of chronic alcohol use. Med Sci Monit 2003; 9(12): RA285-90.
43. Sadovnikov A.I. Cirrhosis of the liver. The etiology, pathogenesis, clinical manifestations, diagnosis, treatment. Russkiy Meditsinskiy Zhurnal 2003; 5 (2): 37-42. Russian (Садовникова И.И. Циррозы печени. Вопросы этиологии, патогенеза, клиники, диагностики, лечения. Русский Медицинский Журнал 2003;5(2):37–42).
44. Enoch M.A., Goldman D. Problem Drinking and Alcoholism: Diagnosis and Treatment. Am Fam Physician 2002;65(3):441-9.
45. Hock B., Schwarz M., Domke I., et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005;100(10):1477-86.
46. Tarasova O.I., Ogurtsov P.P., Mazurchik N.V., Moiseyev V.S. Modern ofl aboratory markers of alcohol consumption. Klinicheskaya Farmakologiya i Terapiya 2007; (1): 45-50. Russian (Тарасова О.И., Огурцов П.П., Мазурчик Н.В., Моисеев В.С. Современные лабораторные маркеры употребления алкоголя. Клиническая Фармакология и Терапия 2007; (1): 45-50).
47. Proude E., Lopatko O., Lintzeris N. et al. The Treatment of Alcohol Problems. A Review of the Evidence Prepared for the Australian Government Department of Health and Ageing. Guidelines for the Treatment of Alcohol Problems. Canberra: Australian Government Department of Health and Aged Care; 2009.
48. Delanghe J.R., De Buyzere M.L. Carbohydrate deficient transferrin and forensic medicine. Clin Chim Acta 2009;406(1-2):1-7.
49. Wursthttp://alcalc.oxfordjournals.org/content/39/1/33.long - target-1 F.M., Alexson S., Wolfersdorf M. Concentration of fatty acid ethyl esters in hair of alcoholics: comparison to other biological state markers and self reported-ethanol intake. Alcohol Alcohol 2004;39(1):33-8.
50. Franzini M., Fornaciari I., Vico T. et al. High-sensitivity γ-glutamyltransferase fraction pattern in alcohol addicts and abstainers. Drug Alcohol Depend 2013;127(1-3):239-42.
51. Mariann RP. Alcoholic Cardiomyopathy: Incidence, Clinical Characteristics, and Pathophysiology. Chest 2002; 121(5): 1638-50.
52. Kinny E.L., Wright R.J., Caldwell J.W. Risk factors in alcoholic cardiomyopathy. Angiol J Vasc Dis1989;4:270-5.
53. Ilomaki J, Hajat A, Jussi Kauhanen J. Relationship between alcohol consumption and myocardial infarction among ageing men using a marginal structural model. Eur J Public Health 2012; 22 (6): 825-30.
54. Yoshimura A, Kimura M, Nakayama H et al. Efficacy of Disulfiram for the Treatment of Alcohol Dependence Assessed with a Multicenter Randomized Controlled Trial. Alcohol Clin Exp Res 2014;38(2):572-8.
55. Brennan JL, Leung JG, Gagliardi JP et al. Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clin Pharmacol 2013; 5: 99-107.
56. Pettinati HM, Silverman BL, Battisti JJ et al. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res 2011;35(10):1804-11.
57. Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag 2007;3(5):741-9.
58. Fucito L.M., Park A, Gulliver S.B. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry 2012;72(10):832-8.
59. Litten R.Z., Ryan M.L., Fertig J.B. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013;7(4):277-86.
60. Mason B.J., Quello S., Goodell V., et al. Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial. JAMA Intern Med2014;174(1):70-7.
61. European Medicines Agency European Public Assessment Report (EPAR) for Selincro® EMEA/H/C/002583/0000. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002583/WC500140326.pdf. Accessed by 20.01.2014.
62. van den Brink W., Aubin H.J., Bladstrom A., et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 2013; 48(5): 570-8.
63. Mann K., Bladstrom A., Torup L. et al. Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene. J Biological Psychiatry 2013; 73(8): 706-13.
64. Gual A., He Y., Torup L., van den Brink W., et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23(11): 1432-42.
65. Kranzler H.R., McKay J.R. Personalized treatment of alcohol dependence. Curr Psychiatry Rep 2012;14(5):486-93.
Review
For citations:
Yusupova A.O. ALCOHOLIC CARDIOMYOPATHY: BASIC ASPECTS OF EPIDEMIOLOGY, PATHOGENESIS AND PHARMACOTHERAPY. Rational Pharmacotherapy in Cardiology. 2014;10(6):651-658. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-6-651-658
Views:
1902
Email this article 